linjc16/ctgov huggingface dataset:
Testicular Torsion

Study Overview
=================
Brief Summary
-----------------
Background: Testicular torsion is a scrotal emergency that results in impaired blood supply to the testis and ischemia of the testis as a result of the rotation of the spermatic cord around itself. The etiology of testicular torsion is not clear, but various predisposing factors are responsible for the occurrence of testicular torsion. Recently, with the discovery of Toll-Like Receptors (TLRs), new horizons have been opened in the field of innate immune system-related diseases. Objective: To mediate the relationship between testicular torsion and TLR4 receptors. Material-Method: Testicular specimens of patients who developed testicular ischemia after testicular torsion and underwent orchiectomy between 2012-2022 were reached. A study of TLR 4 receptors was performed in these testicular specimens. The patients were divided into two groups according to their ages newborns and adolescents.

Detailed Description
-----------------
Analysis of 32 newborns and 32 adolescents between the ages of 14 and 16 (mean age was 15.17 ± 0.98) testicular tissue lysate using Toll-Like Receptor antibody 4 (TLR4) ELISA (Enzyme-Linked ImmunoSorbent Assay). Toll-like receptor 4 is a transmembrane protein that in humans is encoded by the TLR4 gene. Its activation leads to the production of inflammatory cytokines.

Official Title
-----------------
Is There a Toll-like 4 Receptor Relationship in Patients With Testicular Torsion?

Conditions
-----------------
Testicular Torsion and TLR 4 Was Investigated

Intervention / Treatment
-----------------
* Genetic: Toll-like receptor 4


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: testicular torsion newborn, adolescent, Exclusion Criteria: orchitis, urinary infection, trauma,

Ages Eligible for Study
-----------------
Minimum Age: 0 Days
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1<br>Newborn | Genetic: Toll-like receptor 4<br>* Toll-like receptor 4<br>|
| Experimental: Group 2<br>adolescent | Genetic: Toll-like receptor 4<br>* Toll-like receptor 4<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toll-like receptor 4 positives or negative | testicular torsion | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
testicular torsion,, Toll-like receptors (TLR),, child, newborn, adolescent
Brief Cognitive Behavioral Therapy for People With Physical Disabilities

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the effectiveness of a psychotherapy (non-medication) treatment, Brief Cognitive Behavioral Therapy for Suicide Prevention, in reducing suicide ideation and attempts for people with physical disabilities.

Official Title
-----------------
Telehealth-delivered Brief Cognitive Behavioral Therapy to Prevent Suicides in People With Physical Disabilities

Conditions
-----------------
Suicide, Suicide, Attempted, Suicidal Ideation, Disability Physical, Disability Hearing, Disability, Vision

Intervention / Treatment
-----------------
* Behavioral: Brief Cognitive Behavioral Therapy for People with Physical Disabilities


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age Disability impacting vision, hearing, or mobility Past-week suicidal ideation or past-month suicide attempt Exclusion Criteria: Inability to provide informed consent Lack of internet connection and web camera

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Brief Cognitive Behavioral Therapy for People with Physical Disabilities<br> | Behavioral: Brief Cognitive Behavioral Therapy for People with Physical Disabilities<br>* 12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scaler for Suicide Ideation | Past-week suicidal ideation severity | Weekly change through treatment completion, an average of 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-Injurious Thoughts and Behaviors Interview-Revised | Suicide attempt since last assessment | Through treatment completion, an average of 3 months |
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.

Official Title
-----------------
Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their previous therapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IDet users<br> | Drug: insulin detemir<br>* Prescribed at the discretion of the physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c (glycaemic haemoglobin) |  |  | 
| Fasting plasma glucose (FBG) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight change |  |  | 
| Adverse drug reactions (ADR) |  |  | 
| Serious adverse drug reactions (SADR) |  |  | 
| Hypoglycaemic episodes |  |  |
Use Of Virtual Reality To Reduce Anxiety And Pain During Repair Of Perineal Laceration And Episiotomy

Study Overview
=================
Brief Summary
-----------------
Virtual Reality will be used to decrease anxiety and pain during suturing of episiotomy and perineal lacerations

Detailed Description
-----------------
Perineal lacerations and episiotomies are common after vaginal birth. Surgical repair of these conditions can cause discomfort and anxiety for the post-partum woman. The purpose of this research is to determine if the use of virtual reality (VR) during repair of a perineal laceration or episiotomy can decrease the anxiety level of the woman. Other parameters that will be measured will be vital signs, time of procedure, and pain level. 84 eligible healthy women after spontaneous or instrumental vaginal birth will be enrolled. Allocation will be randomized by previous sealed envelopes. 42 in the VR group and 42 in the control group. The 42 women in the VR group will have the device placed band in use before the onset of the procedure. Anxiety level will be measured post-procedure by (STAI) State Inventory Anxiety Trait. Pain will be measure by VAS. Assuming a significant anxiety level of 60% in women undergoing repair of a perineal laceration of episiotomy, in order to demonstrate a reduction to 30% in women using VR with a power of 80% and alpha of 0.05, 42 women will be needed in each group.

Official Title
-----------------
Use Of Virtual Reality To Reduce Anxiety And Pain During Repair Of Perineal Laceration

Conditions
-----------------
Anxiety, Perineum; Injury, Episiotomy Wound

Intervention / Treatment
-----------------
* Device: Virtual Reality for Anxiety Reduction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-partum vaginal delivery, spontaneous or instrumental Episiotomy or 1st or 2nd degree perineal tear informed consent Exclusion Criteria: Cesarean delivery 3rd or 4th degree perineal tear no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interventional<br>use of virtual reality (VR) | Device: Virtual Reality for Anxiety Reduction<br>* Virtual Reality for Anxiety Reduction during suturing of perineum<br>|
| No Intervention: Control<br>no use of VR | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiety Level | questionairre | Immediately after procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Level | questionairre | Immediately after procedure |
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy was done and histopathological examinations were done to evaluate the pathology in these patients.

Detailed Description
-----------------
Study design and settings: Cross sectional descriptive studies conducted from December 2017 till January 2021. Patients: 80 patients with supracervical hysterectomy recruited at Tanta University Hospital, gynecology clinics will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The exclusion criteria were patients with total hysterectomy, hysterectomies for malignant indications, and refusal to participate. Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint. Intervention: under general anesthesia cervical biopsy (4 quadrants) were taken from all patients and was sent for histopathological examinations.

Official Title
-----------------
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Conditions
-----------------
CIN, Cancer of Cervix, Cervicitis

Intervention / Treatment
-----------------
* Procedure: Cervical biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all symptomatizing patients following supracervical hysterectomy, Exclusion Criteria: with total hysterectomy, hysterectomies for malignant indications, refusal to participate.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: All patients suffering after supracervical hysterectomy
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biopsy<br>four quadrant biopsy | Procedure: Cervical biopsy<br>* 4 quadrant biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of cervical neoplasia or cancer incidence | Detection of number of cases diagnosed with cervical Cervical intraepithelial neoplasia, or malignancy by histopathological examination | 1 year | 
| Detection of chronic cervicitis incidence | Detection of number of cases diagnosed with inflammatory cells and other markers of inflammation | 1 year |
Dysfunctional Hemoglobin CO-ox

Study Overview
=================
Brief Summary
-----------------
The study verifies accuracy of a new pulse co-oximeter in the presence of elevated carboxyhemoglobin levels.

Official Title
-----------------
Dysfunctional Hemoglobin

Conditions
-----------------
Elevated Levels of Carboxyhemoglobin

Intervention / Treatment
-----------------
* Device: Pulse Co-Ox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject is male or female. The subject is of any racial or ethnic group. The subject is between 18 years and 45 years of age. The subject does not have significant medical problems. The subject is willing to provide written informed consent and is willing and able to comply with study procedures. Exclusion Criteria: Has a BMI greater than 31 Has had any relevant injury at the sensor location site Has deformities or abnormalities that may prevent proper application of the device under test. Has a known respiratory condition. Is currently a smoker. Has a known heart or cardiovascular condition. Is currently pregnant. Is female and actively trying to get pregnant. Has a clotting disorder. Has Raynaud's Disease. Is known to have a hemoglobinopathy such as (anemia, bilirubinemia, sickle-cell anemia, inherited or congenital methemoglobinemia). The subject has a COHb greater than 3% or MetHb greater than 2%. Has taken blood thinners or medication with aspirin within the last 24 hours. Has unacceptable collateral circulation from the ulnar artery. Has donated more than 300 mL of blood within one month prior to start of study. Is unwilling or unable to provide written informed consent to participate in the study. Is unwilling or unable to comply with the study procedures for the primary objectives. Has another health condition which in the opinion of the principal investigator makes him/her unsuitable for testing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Carboxyhemoglobin over the range of 0-15 percent as assessed by co-oximetry. |  | 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen saturation accuracy in conditions of elevated carboxyhemoglobin. |  | 3 hours |
A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
Patients with inflammatory bowel disease (IBD) who require methotrexate (MTX)for treatment currently receive this drug by injection. MTX is also available as a pill that can be given by mouth but it is not known how well the drug enters the body in patients with Crohn's disease or ulcerative colitis. This study is being done to compare how much MTX enters the body when the drug is taken by mouth compared to when it is given by injection. If the drug is well absorbed, it may allow patients to receive the drug by mouth.

Official Title
-----------------
A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease

Conditions
-----------------
Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Drug: Methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Adult or pediatric patients with IBD (CD or UC) currently receiving MTX as part of their clinical care. Patients must be receiving weekly MTX at a dose between 7.5 and 40 mg/m2. Weight >= 12 kg. Normal serum creatinine.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Crossover Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Methotrexate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of procedural differences during the Valsalva maneuver and deep breathing test in autonomic nervous system testing.

Official Title
-----------------
Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup

Conditions
-----------------
Autonomic Nervous System Diseases

Intervention / Treatment
-----------------
* Other: Autonomic Function Testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male ≥ 18 year normal ECG-12 Exclusion Criteria: any known disease smoking any intake of regular medicine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br> | Other: Autonomic Function Testing<br>* Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure changes to cardiovascular adrenergic activation |  | 3 hours | 
| Heart rate changes to parasympathetic activation |  | 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expiratory pressure during the Valsalva maneuver |  | 3 hours | 
| Expiratory duration during the Valsalva maneuver |  | 3 hours | 
| Air volume exchanged per respiratory cycle during deep respiration |  | 3 hours |
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
Tenofovir (TDF)-containing regimens may be associated with decreasing renal function in HIV-infected patients concurrently treated with boosted PI's and/or have co-morbid conditions including diabetes mellitus, hypertension, anemia, hepatitis B, and hepatitis C.

Detailed Description
-----------------
COL109413 is a Phase IV retrospective database study involving the review of medical records of approximately 850 HIV-infected patients treated at a single center (Peabody Health Clinic, Dallas, Texas) and followed for up to a 4-year period (2003-2006). Patients whose GFR decreased >25% from baseline (BL) will be identified and their disease and treatment characteristics will be compared to those of patients whose GFR did not change. GFR will be calculated by both the MDRD and the Cockcroft-Gault methods. The following information will be noted: patient age, weight, gender, race/ethnicity, viral load, CD4 cell count, serum creatinine and other available laboratory data, start of HAART therapy (TDF - vs non-TDF-containing), changes in drug treatment, co-morbidities (hypertension, diabetes mellitus, anemia, hepatitis C virus or hepatitis B virus infection), drug treatment for co-morbidities and non-HIV-related illnesses, and adherence by prescription refill. The study endpoints will be: time from treatment initiation-to-event (GFR decrease >25% from BL) analysis between TDF-containing vs non-TDF-containing antiretroviral therapy; number of patients who convert from National Kidney Foundation-defined mild to moderate renal impairment or from moderate to severe renal impairment in the TDF vs non-TDF-treated patients; effect of co-morbidities and concomitant medications on time to GFR decrease >25% from BL.

Official Title
-----------------
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

Conditions
-----------------
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV positive patients seen between 2003 and 2006 Exclusion Criteria: Fewer than two laboratory results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human Immunodeficiency Viruses, Glomerular Filtration Rate, Tenofovir, Treatment Experienced